Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.56 |
| ▸ | HTT | P42858 | 2/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.56 |
| ▸ | GALR3 | O60755 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | ERN1 | O75460 | 1/20 | 0.54 |
| ▸ | GPR35 | Q9HC97 | 5/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.41 |
| ▸ | SNCA | P37840 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | TTR | P02766 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27001787 | 0.83 | ERN1 (0.54) | MEN1KMT2AHTTL3MBTL1ERN1 | |
| SCHEMBL4144580 | 0.81 | ERN1 (0.69) | MEN1KMT2AHTTL3MBTL1ERN1 | |
| Dinoterb SCHEMBL29487271 | 0.81 | KMT2A (0.79) | MEN1KMT2AHTTL3MBTL1GALR3 | |
| Dinoterb SCHEMBL53794 | 0.81 | KMT2A (0.79) | MEN1KMT2AHTTL3MBTL1GALR3 | |
| SCHEMBL17500084 | 0.81 | GPR35 (0.69) | MEN1KMT2AHTTL3MBTL1GALR3 | |
| SCHEMBL397532 | 0.81 | GPR35 (0.62) | MEN1KMT2AHTTL3MBTL1GALR3 | |
| Dinoterb SCHEMBL8535102 | 0.81 | KMT2A (0.79) | MEN1KMT2AHTTL3MBTL1GALR3 | |
| Dinoterb SCHEMBL424259 | 0.79 | KMT2A (0.77) | MEN1KMT2AHTTL3MBTL1GALR3 | |
| SCHEMBL699420 | 0.79 | MEN1 (0.56) | MEN1KMT2AHTTL3MBTL1GALR3 | |
| SCHEMBL12678820 | 0.79 | ALDH1A1 (0.40) | MEN1KMT2AHTTL3MBTL1GALR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1988902-B1 | PIPERAZINE DERIVATIVES | MS SCIENCE CORP (JP) | 2011-11-23 | — | — | EP | claimed |
| EP-1928861-B1 | 4- (IH-INDAZOL-5-YL-AMINO)-QUINAZOLINE COMPOUNDS AS ERBB RECEPTOR TYROSINE KINASE INHIBITORS FOR THE TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2010-11-17 | — | — | EP | claimed |
| EP-1487806-B1 | 4-ANILINO QUINAZOLINE DERIVATIVES AS ANTIPROLIFERATIVE AGENTS | ASTRAZENECA AB (SE) | 2010-07-07 | — | — | EP | claimed |
| EP-2697197-B1 | PYRROLO SULFONAMIDE COMPOUNDS FOR MODULATION OF ORPHAN NUCLEAR RECEPTOR RAR-RELATED ORPHAN RECEPTOR-GAMMA (RORGAMMA, NR1F3) ACTIVITY AND FOR THE TREATMENT OF CHRONIC INFLAMMATORY AND AUTOIMMUNE DISEASES | PHENEX PHARMACEUTICALS AG (DE) | 2015-06-03 | — | — | EP | disclosed |
| US-8946446-B2 | Pyrrolo sulfonamide compounds for modulation of orphan nuclear receptor RAR-related orphan receptor-γ (ROR-γ, NR1F3) activity and for the treatment of chronic inflammatory and autoimmune diseases | PHENEX PHARMACEUTICALS AG (DE) | 2015-02-03 | — | — | US | disclosed |
| US-20140142082-A1 | PYRROLO SULFONAMIDE COMPOUNDS FOR MODULATION OF ORPHAN NUCLEAR RECEPTOR RAR-RELATED ORPHAN RECEPTOR-GAMMA (ROR-GAMMA, NR1F3) ACTIVITY AND FOR THE TREATMENT OF CHRONIC INFLAMMATORY AND AUTOIMMUNE DISEASES | PHENEX PHARMACEUTICALS AG (DE) | 2014-05-22 | — | — | US | disclosed |
| EP-2385039-B1 | 2-Iminoisoindolinone derivatives as thrombin receptor antagonists | EISAI R&D MAN CO LTD (JP) | 2014-03-12 | — | — | EP | disclosed |
| EP-2697197-A1 | PYRROLO SULFONAMIDE COMPOUNDS FOR MODULATION OF ORPHAN NUCLEAR RECEPTOR RAR-RELATED ORPHAN RECEPTOR-GAMMA (RORGAMMA, NR1F3) ACTIVITY AND FOR THE TREATMENT OF CHRONIC INFLAMMATORY AND AUTOIMMUNE DISEASES | Phenex Pharmaceuticals AG (DE) | 2014-02-19 | — | — | EP | disclosed |
| WO-2012139775-A1 | PYRROLO SULFONAMIDE COMPOUNDS FOR MODULATION OF ORPHAN NUCLEAR RECEPTOR RAR-RELATED ORPHAN RECEPTOR-GAMMA (RORGAMMA, NR1F3) ACTIVITY AND FOR THE TREATMENT OF CHRONIC INFLAMMATORY AND AUTOIMMUNE DISEASES | PHENEX PHARMACEUTICALS AG (DE) | 2012-10-18 | — | — | WO | disclosed |
| EP-2511263-A1 | Pyrrolo sulfonamide compounds for modulation of orphan nuclear receptor RAR-related orphan receptor-gamma (RORgamma, NR1F3) activity and for the treatment of chronic inflammatory and autoimmune diseases | Phenex Pharmaceuticals AG (DE) | 2012-10-17 | — | — | EP | disclosed |
| EP-1614680-B1 | Process for preparing 2-iminopyrrolidine derivatives | EISAI R&D MAN CO LTD (JP) | 2011-12-21 | — | — | EP | disclosed |
| US-7244730-B2 | 2-iminopyrrolidine derivatives | EISAI CO., LTD (JP) | 2007-07-17 | — | — | US | disclosed |
| CN-1321996-C | Process for producing 2-iminopyrrolidine derivative | SANITATION STUFF R & D MANAGE (JP) | 2007-06-20 | — | — | CN | disclosed |
| CN-1754880-A | Process for preparing 2-iminopyrrolidine derivatives | EISAI CO LTD (JP) | 2006-04-05 | — | — | CN | disclosed |
| CN-1243735-C | 2-iminopyrrolidine derivatives | EISAI CO LTD (JP) | 2006-03-01 | — | — | CN | disclosed |
| CN-1733725-A | Process for preparing 2-iminopyrrolidine derivatives | EISAI CO LTD (JP) | 2006-02-15 | — | — | CN | disclosed |
| US-20050245592-A1 | 2-Iminopyrrolidine derivatives | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2005-11-03 | — | — | US | disclosed |
| US-20050004204-A1 | 2-Iminopyrrolidine derivatives | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2005-01-06 | — | — | US | disclosed |
| CN-1503784-A | 2-iminopyrrolidine derivatives | ������������ʽ���� | 2004-06-09 | — | — | CN | disclosed |
| EP-1391451-A1 | 2-IMINOPYRROLIDINE DERIVATES | Eisai Co., Ltd. (JP) | 2004-02-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050245592-A1 | 2-Iminopyrrolidine derivatives | H1-2, H1-3, H1-0 | MEN1 891/4885KMT2A 2082/4885HTT 270/4885 |
| US-20050004204-A1 | 2-Iminopyrrolidine derivatives | H1-2, H1-3, H1-0 | MEN1 859/4885KMT2A 2110/4885HTT 272/4885 |
| US-20140142082-A1 | PYRROLO SULFONAMIDE COMPOUNDS FOR MODULATION OF ORPHAN NUCLEAR RECEPTOR RAR-RELATED ORPHAN RECEPTOR-GAMMA (ROR-GAMMA, NR1F3) ACTIVITY AND FOR THE TREATMENT OF CHRONIC INFLAMMATORY AND AUTOIMMUNE DISEASES | RORA, RORB, RORC | MEN1 4811/4885KMT2A 1621/4885HTT 4323/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.